004310.KO Hyundai Pharm
- Market cap
- KRW 205B
- P/E
- 142.5x
- P/B
- 1.53x
- ROE
- 3.5%
- Dividend yield
- 0.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is 004310.KO undervalued?
Graham numberThe Graham number of Hyundai Pharm cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hyundai Pharm fundamental analysis
No fundamental analysis for Hyundai Pharm yet.
Hyundai Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilator…
Full company profileHyundai Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hyundai Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 120B | 130B | 134B | 135B | 133B | 140B | 163B | 181B | 176B | 192B | 211B |
| Gross Profit | 47.1B | 62.0B | 63.6B | 63.9B | 58.3B | 56.3B | 68.8B | 76.6B | 73.4B | 79.6B | 84.0B |
| Operating Income | 2.33B | 2.01B | 1.22B | 1.56B | 3.05B | -1.57B | 7.97B | 6.93B | 181M | 4.16B | 7.92B |
| EBITDA | - | 4.94B | 797M | 5.71B | 7.41B | 671M | 10.1B | 13.2B | 3.94B | 8.47B | 12.9B |
| Net Income | 1.26B | 1.46B | 929M | 1.16B | 2.19B | -3.17B | -165M | 6.12B | -575M | 2.52B | 4.46B |
| EPS | - | 62 | 34 | 43 | 78 | -114 | -5.98 | 230 | -22 | 81 | 144 |
| Balance Sheet | |||||||||||
| Total Assets | 151B | 155B | 159B | 145B | 158B | 164B | 181B | 155B | 156B | 163B | 227B |
| Total Liabilities | 50.5B | 56.5B | 51.8B | 57.9B | 67.4B | 77.3B | 94.6B | 70.0B | 77.3B | 81.1B | 98.3B |
| Shareholders' Equity | 100B | 98.1B | 107B | 87.6B | 90.1B | 86.6B | 86.6B | 84.7B | 79.1B | 82.1B | 129B |
| Cash & Short-term Investments | 8.62B | 8.23B | 7.36B | 7.40B | 13.3B | 21.6B | 30.3B | 16.2B | 10.3B | 2.50B | 12.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.75B | -1.98B | 2.83B | 6.96B | 10.8B | 5.13B | 11.6B | -4.55B | -2.37B | -123M | 11.3B |
| Capital Expenditure | 3.68B | 3.10B | 2.67B | 2.36B | 6.40B | 6.81B | 6.58B | 6.10B | 11.2B | 5.86B | 6.75B |
| Free Cash Flow | - | -5.08B | 168M | 3.35B | 4.40B | -1.68B | 5.04B | -10.6B | -13.6B | -5.99B | 4.50B |
| Ratios | |||||||||||
| ROE | 1.3% | 1.5% | 0.9% | 1.3% | 2.4% | -3.7% | -0.2% | 7.2% | -0.7% | 3.1% | 3.5% |
| ROA | 0.8% | 0.9% | 0.6% | 0.8% | 1.4% | -1.9% | -0.1% | 4.0% | -0.4% | 1.5% | 2.0% |
| Net Profit Margin | 1.1% | 1.1% | 0.7% | 0.9% | 1.6% | -2.3% | -0.1% | 3.4% | -0.3% | 1.3% | 2.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hyundai Pharm dividends
- Dividend yield
- 0.38%
- Forward dividend
- 30.00 KRW
- Payout ratio
- 31.1%
- Ex-dividend date
- Mar 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 784M | 25 | 31.1% |
| 2024 | KRW 923M | 35 | - |
| 2023 | KRW 826M | 31 | 13.5% |
| 2022 | KRW 836M | 30 | - |
| 2021 | KRW 1.18B | 42 | - |
| 2020 | KRW 1.21B | 44 | 55.5% |
| 2019 | KRW 1.23B | 46 | 106.4% |
| 2018 | KRW 1.18B | 43 | 127.0% |
| 2017 | KRW 1.15B | 49 | 78.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Mar 17, 2008.
Who owns Hyundai Pharm
- Insiders 31.49%
- Institutions 0.49%
- Public & others 68.02%
- Shares outstanding 30.9M
- Free float 14.9M
Hyundai Pharm company profile
- Company name
- Hyundai Pharm
- Ticker
- 004310.KO
- ISIN
- KR7004310009
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- November
- Address
- Hyundai Pharm Building, Seoul, South Korea, 06121
- Website
- hyundaipharm.co.kr
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.
Hyundai Pharm management
1- Sang-Jun LeePresident · born 1976